CIK 0000894158
- Non-accelerated filer
- Smaller reporting company
Theriva Biologics, Inc.
Sign in to watch- Ticker
- TOVX
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 133808303
- Phone
- +1 734-332-7800
- Business address
- 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MD, 20850
- Former names
- Synthetic Biologics, Inc., ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD PHARMACEUTICALS INC, SHEFFIELD MEDICAL TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-05 | SHALLCROSS STEVEN A CEO and CFO | Grant or award · Stock Options (right to buy) | +475,000 | 475,000 | ||
| 2025-04-29 | SHALLCROSS STEVEN A CEO and CFO | Grant or award · Stock Options (right to buy) | +190,000 | 190,000 | ||
| 2023-12-14 | SHALLCROSS STEVEN A CEO and CFO | Grant or award · Stock Options (right to buy) | +700,000 | 700,000 | ||
| 2023-06-07 | SHALLCROSS STEVEN A CEO and CFO | Purchase | +14,000 | $0.69 | $10K | 250,000 |
| 2023-06-06 | SHALLCROSS STEVEN A CEO and CFO | Purchase | +26,000 | $0.63 | $16K | 236,000 |
| 2023-02-10 | SHALLCROSS STEVEN A CEO and CFO | Purchase | +25,000 | $1.04 | $26K | 210,000 |
| 2023-02-02 | SHALLCROSS STEVEN A CEO and CFO | Purchase | +25,000 | $0.94 | $24K | 185,000 |
| 2023-01-25 | SHALLCROSS STEVEN A CEO and CFO | Purchase | +25,000 | $0.87 | $22K | 160,000 |
| 2023-01-20 | SHALLCROSS STEVEN A CEO and CFO | Purchase | +25,000 | $0.75 | $19K | 135,000 |
| 2022-12-29 | SHALLCROSS STEVEN A CEO and CFO | Purchase | +100,000 | $0.44 | $44K | 110,000 |
| 2022-12-15 | SHALLCROSS STEVEN A CEO and CFO | Grant or award · Stock Options (right to buy) | +475,000 | 475,000 | ||
| 2021-12-23 | SHALLCROSS STEVEN A CEO and CFO | Grant or award · Stock Options (right to buy) | +650,000 | 650,000 | ||
| 2021-05-10 | SHALLCROSS STEVEN A CEO and CFO | Purchase | +50,000 | $0.49 | $25K | 100,000 |
| 2020-12-30 | SHALLCROSS STEVEN A CEO and CFO | Grant or award · Stock Options | +450,000 | 450,000 | ||
| 2019-12-04 | SHALLCROSS STEVEN A CEO and CFO | Grant or award · Stock Options | +450,000 | 450,000 | ||
| 2019-08-23 | SHALLCROSS STEVEN A CEO and CFO | Purchase | +50,000 | $0.42 | $21K | 50,000 |
| 2018-12-06 | SHALLCROSS STEVEN A CEO and CFO | Grant or award · Stock Options | +200,000 | 200,000 | ||
| 2017-12-20 | SHALLCROSS STEVEN A Interim CEO and CFO | Grant or award · Stock Options | +550,000 | 550,000 | ||
| 2016-11-30 | SHALLCROSS STEVEN A Chief Financial Officer | Grant or award · Stock Options | +500,000 | 500,000 | ||
| 2015-12-04 | SHALLCROSS STEVEN A Chief Financial Officer | Grant or award · Stock Options | +100,000 | 100,000 |
Page 1 of 2 · 21 trades